Alpha2-macroglobulin as a promising biomarker for cerebral small vessel disease in acute ischemic stroke patients
- 443 Downloads
Alpha2-macroglobulin is a protease inhibitor that enhances procoagulant properties via the neutralization of plasmin, plasminogen activators and metalloproteinases. Additionally, alpha2-macroglobulin is thought to be involved in inflammatory reactions as a carrier protein for interleukin-6 (IL-6). The objective of this study was to evaluate the usefulness of alpha2-macroglobulin as a biomarker for cerebrovascular diseases. Patients with acute ischemic stroke (n = 159; 93 male and 66 female, 71.6 ± 10.3 years) and patients with no previous history of stroke (n = 77; 38 male and 39 female, 70.7 ± 9.5 years) were consecutively enrolled in this study. White matter lesions were assessed via the fluid-attenuated inversion recovery image of magnetic resonance images using the Fazekas classification. The serum alpha2-macroglobulin levels were measured by nephelometry. The serum alpha2-macroglobulin levels at admission in patients with acute ischemic stroke were higher than those in the control patients (230.2 ± 73.7 vs. 205.0 ± 55.8 mg/dl, p = 0.009). The serum alpha2-macroglobulin levels were positively correlated with age and the severity of the white matter lesions (R 2 = 0.048, p < 0.001 and R 2 = 0.058, p < 0.001, respectively), although there was no significant association between serum alpha2-macroglobulin levels and IL-6 levels. In addition, multivariate analysis showed that increased serum alpha2-macroglobulin levels were independently associated with the severity of white matter lesions [standardized partial regression coefficient (β) 0.102, p = 0.026]. Increased serum alpha2-macroglobulin levels might be involved in the pathophysiology of acute ischemic stroke. Furthermore, serum alpha2-macroglobulin levels, which were associated with high-grade white matter lesions, may reflect the chronic pathophysiological condition of cerebral small vessel disease.
KeywordsNeurology Biological markers Stroke Inflammation Leukoaraiosis
We would like to express our gratitude to Kobayashi, Furuno, Sasanishi and Hironaka for their technical assistance. This study was supported in part by research grants from the Smoking Research Foundation, the Tsuchiya Foundation, the Japan Science and Technology Agency and the Japan Heart Foundation.
Conflicts of interest
- 10.Cáceres LC, Bonacci GR, Sánchez MC, Chiabrando GA (2010) Activated α(2) macroglobulin induces matrix metalloproteinase 9 expression by low-density lipoprotein receptor-related protein 1 through MAPK-ERK1/2 and NF-κB activation in macrophage-derived cell lines. J Cell Biochem 111:607–617PubMedCrossRefGoogle Scholar
- 12.Ahmad J, Singh M, Saleemuddin M (2001) A study of plasma alpha-2-macroglobulin levels in type 2 diabetic subjects with micro albuminuria. J Assoc Physic India 49:1062–1065Google Scholar
- 13.Watzke H, Schernthaner G, Schnack C, Schwarz HP, Prskavec F, Freyler H (1988) Coagulation factors of contact phase of haemostasis are normal in well-controlled type-I diabetic patients despite presence of diabetic retinopathy. Diabet Res 7:197–200Google Scholar
- 14.Hosomi N, Aoki S, Matsuo K, Deguchi K, Masugata H, Murao K, Ichihara N, Ohyama H, Dobashi H, Nezu T, Ohtsuki T, Yasuda O, Soejima H, Ogawa H, Izumi Y, Kohno M, Tanaka J, Matsumoto M (2012) Association of serum anti-periodontal pathogen antibody with ischemic stroke. Cerebrovasc Dis 34:385–392PubMedCrossRefGoogle Scholar
- 26.Carmichael O, Schwarz C, Drucker D, Fletcher E, Harvey D, Beckett L, Jack CR, Weiner M, DeCarli C, Initiative AsDN (2010) Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative. Arch Neurol 67:1370–1378PubMedCrossRefGoogle Scholar
- 30.Myllykangas L, Polvikoski T, Sulkava R, Verkkoniemi A, Crook R, Tienari PJ, Pusa AK, Niinistö L, O’Brien P, Kontula K, Hardy J, Haltia M, Pérez-Tur J (1999) Genetic association of alpha2-macroglobulin with Alzheimer’s disease in a Finnish elderly population. Ann Neurol 46:382–390PubMedCrossRefGoogle Scholar
- 33.Rudrasingham V, Wavrant-De Vrièze F, Lambert JC, Chakraverty S, Kehoe P, Crook R, Amouyel P, Wu W, Rice F, Pérez-Tur J, Frigard B, Morris JC, Carty S, Petersen R, Cottel D, Tunstall N, Holmans P, Lovestone S, Chartier-Harlin MC, Goate A, Hardy J, Owen MJ, Williams J (1999) Alpha-2 macroglobulin gene and Alzheimer disease. Nat Genet 22:17–19PubMedCrossRefGoogle Scholar